Pateclizumab

Pateclizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetlymphotoxin alpha
Clinical data
Other namesMLTA3698A
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6436H9910N1710O2004S44
Molar mass144716.68 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.[1][2][3][4][5][6]

This drug was developed by Genentech/Roche.

References

  1. World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association.
  3. Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC (October 2014). "Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)". Arthritis Res. Ther. 16 (5): 467. doi:10.1186/s13075-014-0467-3. PMC 4243296. PMID 25359150.
  4. Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC (January 2012). "Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial". Arthritis Res. Ther. 14 (1): R6. doi:10.1186/ar3554. PMC 3392792. PMID 22225620.
  5. Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G (August 2016). "Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates". Reprod. Toxicol. 63: 82–95. doi:10.1016/j.reprotox.2016.05.014. PMID 27211603.
  6. Hirose T, Fukuma Y, Takeshita A, Nishida K (June 2018). "The role of lymphotoxin-α in rheumatoid arthritis". Inflamm. Res. 67 (6): 495–501. doi:10.1007/s00011-018-1139-6. PMID 29541795. S2CID 3910200.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.